20/20 Biolabs Inc (NASDAQ:AIDX – Get Free Report) was the recipient of a significant decrease in short interest in September. As of September 15th, there was short interest totaling 46,806 shares, a decrease of 50.4% from the August 31st total of 94,280 shares. Based on an average trading volume of 58,991 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.5% of the shares of the stock are short sold.
20/20 Biolabs Price Performance
AIDX stock opened at $0.41 on Wednesday. The business has a fifty day moving average price of $0.50 and a 200 day moving average price of $0.99. 20/20 Biolabs has a fifty-two week low of $0.40 and a fifty-two week high of $50.00. The stock has a market capitalization of $5.22 million and a price-to-earnings ratio of -0.76.
20/20 Biolabs (NASDAQ:AIDX – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.26) EPS for the quarter. The business had revenue of $0.73 million during the quarter.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on 20/20 Biolabs
20/20 Biolabs Company Profile
We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.
Further Reading
- Five stocks we like better than 20/20 Biolabs
- Up All Night: How Nasdaq’s 23-Hour Trading Could Wake Up Wall Street
- 4 Stocks That Could Split Next—and Why Investors Are Watching
- Oura’s IPO Freeze Isn’t the Warning Sign It Looks Like
- Bitcoin Is Bouncing Back—Here are 2 Ways to Play the Rebound
Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.
